Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Sharma S, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, Burris HA 3rd. Sharma S, et al. Among authors: oldenhuis cn. Invest New Drugs. 2014 Feb;32(1):135-44. doi: 10.1007/s10637-013-9952-9. Epub 2013 Apr 16. Invest New Drugs. 2014. PMID: 23589214
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA. Oldenhuis CN, et al. Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16. Clin Colorectal Cancer. 2015. PMID: 25591799 Clinical Trial.
Translating TRAIL-receptor targeting agents to the clinic.
den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, de Vries EG. den Hollander MW, et al. Among authors: oldenhuis cn. Cancer Lett. 2013 May 28;332(2):194-201. doi: 10.1016/j.canlet.2012.04.007. Epub 2012 Apr 21. Cancer Lett. 2013. PMID: 22531313 Review.
Targeting TRAIL death receptors.
Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG. Oldenhuis CN, et al. Curr Opin Pharmacol. 2008 Aug;8(4):433-9. doi: 10.1016/j.coph.2008.06.011. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18625341 Review.
Targeting TRAIL towards the clinic.
Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, de Jong S, Nawrocki ST. Mahalingam D, et al. Among authors: oldenhuis cn. Curr Drug Targets. 2011 Dec;12(14):2079-90. doi: 10.2174/138945011798829357. Curr Drug Targets. 2011. PMID: 21777191
Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, deVries EG, Keller JJ, Offerhaus JA, Giardiello FM, Kleibeuker JH. Koornstra JJ, et al. Among authors: oldenhuis cn. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1608-12. doi: 10.1158/1055-9965.EPI-05-0112. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16030090
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé VMH, van Grevenstein WMU, Elias S, Verkooijen HM, Laclé MM, Bosch LJW, van den Broek D, Meijer GA, Velculescu VE, Fijneman RJA, Vink GR, Koopman M; PLCRC-MEDOCC group. Schraa SJ, et al. BMC Cancer. 2020 Aug 20;20(1):790. doi: 10.1186/s12885-020-07252-y. BMC Cancer. 2020. PMID: 32819390 Free PMC article.
Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
Koevoets EW, Schagen SB, de Ruiter MB, Geerlings MI, Witlox L, van der Wall E, Stuiver MM, Sonke GS, Velthuis MJ, Jobsen JJ, Menke-Pluijmers MBE, Göker E, van der Pol CC, Bos MEMM, Tick LW, van Holsteijn NA, van der Palen J, May AM, Monninkhof EM; PAM study group. Koevoets EW, et al. Breast Cancer Res. 2022 May 26;24(1):36. doi: 10.1186/s13058-022-01530-2. Breast Cancer Res. 2022. PMID: 35619188 Free PMC article. Clinical Trial.